Respiratory syncytial virus epidemiology and effectiveness of infant nirsevimab: 2024 results from the Australian Sentinel Hospital Network (FluCAN-PAEDS)
BACKGROUND Respiratory syncytial virus (RSV) is a leading cause of morbidity and mortality in young children and older adults. A long-acting anti-RSV monoclonal antibody (nirsevimab) and bivalent pre-fusion F-protein pregnancy vaccine became available to prevent RSV in young children in 2024; two RS...
Збережено в:
| Автор: | |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
European Centre for Disease Prevention and Control
2026-01-01
|
| Серія: | Eurosurveillance |
| Предмети: | |
| Онлайн доступ: | https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2026.31.2.2500275 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|